PharmaTelevision - Reinventing Roche’s Pipeline

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Reinventing Roche’s Pipeline

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Despite the current economic climate, Roche’s fundamental strategy has remained the same and, as with many major pharmaceutical companies, their focus is still their pipeline. Andrew Jefferson, interviewed at the recent BioTrinity conference, discusses how his role as Head of Strategic Evaluations fits in with the many different activities of Roche’s Pharma Partnering team. His involvement with many of this group’s deals and partnerships enables him to address issues such as ‘Can you do too many deals?’, ‘Is Roche’s partnering strategy scalable?’ and ‘What makes Roche decide to enter into M&A?’

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Andrew Jefferson, role as Global Head of Strategic Evaluations Roche and how it fits in with the many different activities of Roche's Pharma Partnering team.

Fintan Walton:

Hello and welcome to PharmaVentures Business review here at BioTrinity in Oxford. On this show I have Andrew Jefferson who is Global head of strategic evaluations at Roche. Welcome to the show.

Andrew Jefferson:

Thank you Fintan and thanks for the invite and it's a particular pleasure to be here at Oxford as well home of science.

Fintan Walton:

Good, good. I want to understand your specific role within the Roche Group?

Andrew Jefferson:

Alright, I work in I work for Roche Pharma partnering and is the Pharma partnering organization is Roche's pharmaceutical business development function. So we're a function of about 80 people and then we have a process that we look that we call 00.01.07 find get and manage and I guess I'm in the " the find and get part so I head a team strategic evaluation team that's the team that does the business assessment for partnering opportunities and also does some project leadership for M&A transactions.

Fintan Walton:

So, so how do you then operate with the other parts of the partnering group?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Andrew Jefferson

Global Head of Strategic Evaluations

Andrew Jefferson is the Global Head of Strategic Evaluations within Roche Pharma Partnering based in Basel Switzerland. Andrew leads a team which is responsible for the business assessment of partnering opportunities and project leadership for M &A transactions in line with Roche's global strategy. Andrew has spent nearly 8 years in business assessment, scouting and evaluation having previously held roles as Global Head Surveillance, Analysis and Valuation and Business Development Director within the Acquisitions and Strategic Alliances department of Pharma Partnering. Appointed in 2000 as Business Analyst for the Xenical International Business team, Andrew transferred to the Pharma Partnering in-licensing team in 2001. Prior to joining Roche, Andrew was at Novartis, UK were he held roles in both manufacturing and marketing functions. Andrew gained his MBA from The University of Brighton and has a first class honours degree in Chemistry from The University of Nottingham.

Roche

Roche As a research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeuticproducts and services that deliver significant benefits to patients and healthcare professionals " from early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring. Roche employs over about 80,000 people and sells its products in over 150 countries. The company was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. From the very beginning, Roche's visionary founder focused his company on innovation and on establishing an international presence. Today Roche ranks among the world's leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals.